An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion , which will decide whether or not to retain it. |
Dr. Nimesh Gupta | |
---|---|
![]() | |
Born | December 5, 1980 |
Known for | Virology Immunology Vaccinology |
Scientific career | |
Institutions | Institute Pasteur, Paris, France Centre de Recherche des Cordeliers, Paris, France National Institute of Immunology, India |
Website | https://www.nimeshlab.com/ |
Dr. Nimesh Gupta, an Indian vaccine immunologist, is a senior scientist and the Head of the Vaccine Immunology Laboratory at the National Institute of Immunology in India. His research focuses on understanding T-cell immunity to virus infections and vaccinations . Dr. Gupta also established the Human Immune Monitoring and T-cell Assay Platform for advanced testing of vaccines .
![]() | This section of a biography of a living person does not include any references or sources .(December 2023) |
Nimesh earned his Bachelor of Science in Microbiology and Master of Science in Biotechnology from Jiwaji University, Gwalior. He then completed his Ph.D. in 2011 from Jiwaji University and the Defence Research and Development Organisation (DRDO) in Gwalior.
In 2008, as a Raman Charpak Fellow, Nimesh conducted his doctoral research at the Institut Pasteur in Paris, France. Following this, he pursued postdoctoral research at the Centre de recherche des Cordeliers in Paris, France, where he focused on T-cell immunology and viral immunity. In 2015, he joined the National Institute of Immunology in India as a Scientist and established the Vaccine Immunology Laboratory.
Nimesh's research has primarily focused on investigating T-cell immunity in the context of viral infections and vaccines. His research programs utilize longitudinal cohorts of controlled vaccination and human viral infections, such as Dengue, Japanese encephalitis, and COVID-19. In collaboration with AIIMS, Nimesh published a report on the immune response to SARS-CoV-2 in the Indian population [1] . The study revealed that, prior to the pandemic, the Indian population already possessed cross-reactive T cells to SARS-CoV-2 and demonstrated that the immune memory response (T cells and B cells) to the virus exhibited durability traits [2] . This study provided crucial insights into the type of immunity generated in the Indian population following exposure to SARS-CoV-2.
In a multi-centric collaboration, Nimesh published a report on the characteristics of the immune memory response to inactivated virus vaccine. This study provided evidence on the quality and durability of immune memory established by the inactivated COVID-19 vaccine and its response to SARS-CoV-2 variants . Nimesh's team also contributed essential knowledge on the mechanism of protective immunity induced by the historical live attenuated Japanese encephalitis (JE) vaccine (SA14142) .
Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.
In biology, immunity is the state of being insusceptible or resistant to a noxious agent or process, especially a pathogen or infectious disease. Immunity may occur naturally or be produced by prior exposure or immunization.
Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as syncytia that form when infected cells fuse.
Japanese encephalitis (JE) is an infection of the brain caused by the Japanese encephalitis virus (JEV). While most infections result in little or no symptoms, occasional inflammation of the brain occurs. In these cases, symptoms may include headache, vomiting, fever, confusion and seizures. This occurs about 5 to 15 days after infection.
Original antigenic sin, also known as antigenic imprinting, the Hoskins effect, immunological imprinting, or primary addiction is the propensity of the immune system to preferentially use immunological memory based on a previous infection when a second slightly different version of that foreign pathogen is encountered. This leaves the immune system "trapped" by the first response it has made to each antigen, and unable to mount potentially more effective responses during subsequent infections. Antibodies or T-cells induced during infections with the first variant of the pathogen are subject to repertoire freeze, a form of original antigenic sin.
Viral encephalitis is inflammation of the brain parenchyma, called encephalitis, by a virus. The different forms of viral encephalitis are called viral encephalitides. It is the most common type of encephalitis and often occurs with viral meningitis. Encephalitic viruses first cause infection and replicate outside of the central nervous system (CNS), most reaching the CNS through the circulatory system and a minority from nerve endings toward the CNS. Once in the brain, the virus and the host's inflammatory response disrupt neural function, leading to illness and complications, many of which frequently are neurological in nature, such as impaired motor skills and altered behavior.
A breakthrough infection is a case of illness in which a vaccinated individual becomes infected with the illness, because the vaccine has failed to provide complete immunity against the pathogen. Breakthrough infections have been identified in individuals immunized against a variety of diseases including mumps, varicella (Chickenpox), influenza, and COVID-19. The characteristics of the breakthrough infection are dependent on the virus itself. Often, infection of the vaccinated individual results in milder symptoms and shorter duration than if the infection were contracted naturally.
Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV, and Dengue virus and is monitored for in vaccine development.
An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.
The National Institute of Virology in Pune, India is an Indian virology research institute and part of the Indian Council of Medical Research (ICMR). It was previously known as 'Virus Research Centre' and was founded in collaboration with the Rockefeller Foundation. It has been designated as a WHO H5 reference laboratory for SE Asia region.
The central nervous system (CNS) controls most of the functions of the body and mind. It comprises the brain, spinal cord and the nerve fibers that branch off to all parts of the body. The CNS viral diseases are caused by viruses that attack the CNS. Existing and emerging viral CNS infections are major sources of human morbidity and mortality.
The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.
A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine.
An inactivated vaccine is a type of vaccine that contains pathogens that have been killed or rendered inactive, so they cannot replicate or cause disease. In contrast, live vaccines use pathogens that are still alive. Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.
Akiko Iwasaki is a Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University. She is also a principal investigator at the Howard Hughes Medical Institute. Her research interests include innate immunity, autophagy, inflammasomes, sexually transmitted infections, herpes simplex virus, human papillomavirus, respiratory virus infections, influenza infection, T cell immunity, commensal bacteria, COVID-19, and long COVID.
Shane Patrick Crotty is a professor of immunology in the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology.
Carol Shoshkes Reiss, an American viral immunologist, was a professor at New York University's Department of Biology between 1991 and 2020. She is currently a professor emerita at New York University. Her research focused on the dynamic contest between the mouse immune system and virus replication during central nervous system infection. Reiss was editor-in-chief of the journal Viral Immunology (2000–2006) and is currently editor-in-chief of the journal DNA and Cell Biology (2012–present).
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.
A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.
Endothelial cell tropism or endotheliotropism is a type of tissue tropism or host tropism that characterizes an pathogen's ability to recognize and infect an endothelial cell. Pathogens, such as viruses, can target a specific tissue type or multiple tissue types. Like other cells, the endothelial cell possesses several features that supports a productive viral infection a cell including, cell surface receptors, immune responses, and other virulence factors. Endothelial cells are found in various tissue types such as in the capillaries, veins, and arteries in the human body. As endothelial cells line these blood vessels and critical networks that extend access to various human organ systems, the virus entry into these cells can be detrimental to virus spread across the host system and affect clinical course of disease. Understanding the mechanisms of how viruses attach, enter, and control endothelial functions and host responses inform infectious disease understanding and medical countermeasures.
This article needs additional or more specific categories .(November 2023) |